Darrell White

9.1k citations

134 papers · 1.9k indexed · h-index 23

Impact in

Hematology top 0.5%
- Multiple Myeloma Research and Treatments
Oncology top 2%
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research

Papers in ⓘ

Hematology 118
- Multiple Myeloma Research and Treatments 116
Oncology 67
- Cancer Treatment and Pharmacology 34
- Peptidase Inhibition and Analysis 23

Co-authors: Donna Reece (54 shared papers)Andrew R. Belch (24 shared papers)Philippe Moreau (20 shared papers)Nizar J. Bahlis (26 shared papers)Tony Reiman (37 shared papers)Lotfi Benboubker (9 shared papers)Meletios Α. Dimopoulos (19 shared papers)A. Keith Stewart (7 shared papers)
Journals: Blood (56 papers)Journal of Clinical Oncology (15 papers)Cancer (3 papers)Frontiers in Oncology (3 papers)European Journal Of Haematology (3 papers)
Partner nations: Canada United States Spain

In The Last Decade

Darrell White

126 papers receiving 1.9k citations

Peers

Countries citing papers authored by Darrell White

Since Specialization

Citations

This map shows the geographic impact of Darrell White's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darrell White with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darrell White more than expected).

Fields of papers citing papers by Darrell White

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darrell White. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darrell White. The network helps show where Darrell White may publish in the future.

Co-authors

The 25 scholars most cited alongside Darrell White, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Darrell White Line = papers co-authored together Darrell White links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 134 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study Leukemia ·Nizar J. Bahlis, Meletios Α. Dimopoulos, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, P. Joy Ho, Kihyun Kım, Naoki Takezako, Philippe Moreau, Jonathan L. Kaufman, Maria Krevvata, Christopher Chiu, Xiang Qin, Linda Okonkwo, Sonali Trivedi, Jon Ukropec, Ming Qi, Jesús F. San Miguel	2020	158
2	Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study Annals of Oncology ·Michael A. Rieger, Anders Österborg, Ruth Pettengell, Darrell White, Devinder Gill, Jan Walewski, Evelyn Kuhnt, Markus Loeffler, Michael Pfreundschuh, Anthony D. Ho	2010	139
3	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study The Lancet Haematology ·Paul G. Richardson, Sundar Jagannath, Philippe Moreau, Andrzej Jakubowiak, Marc S. Raab, Thierry Façon, Ravi Vij, Darrell White, Donna Reece, Lotfi Benboubker, Jeffrey A. Zonder, L. Claire Tsao, Kenneth C. Anderson, Eric Bleickardt, Anil Singhal, Sagar Lonial	2015	129
4	Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group Journal of Clinical Oncology ·Christine I. Chen, C. Tom Kouroukis, Darrell White, Michael Voralia, Edward A. Stadtmauer, A. Keith Stewart, James R. Wright, Jean Powers, Wendy Walsh, Elizabeth A. Eisenhauer	2007	126
5	Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma Blood ·Nizar J. Bahlis, Heather J. Sutherland, Darrell White, Michaël Sébag, Suzanne Lentzsch, Rami Kotb, Christopher P. Venner, Cristina Gasparetto, Aldo Del Col, Paola Neri, Donna Reece, Michael Kauffman, Sharon Shacham, Thaddeus J. Unger, Jacqueline Jeha, Jean‐Richard Saint‐Martin, Jatin J. Shah, Christine Chen	2018	102
6	Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T‐cell lymphoma Cancer ·Ethan Toumishey, Angeli Prasad, Greg Dueck, Neil Chua, Daygen L. Finch, James B. Johnston, Richard van der Jagt, Doug Stewart, Darrell White, Andrew R. Belch, Tony Reiman	2014	76
7	Interim report of a phase 2 clinical trial of lenalidomide for T‐cell non‐Hodgkin lymphoma Cancer ·Greg Dueck, Neil Chua, Angeli Prasad, Daygen L. Finch, Doug Stewart, Darrell White, Richard van der Jagt, James B. Johnston, Andrew R. Belch, Tony Reiman	2010	76
8	Types and Frequency of Lesions of the Caruncle American Journal of Ophthalmology ·Carol L. Shields, Jerry A. Shields, Darrell White, James J. Augsburger	1986	70
9	Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma Cancer ·Darrell White, Adetola A. Kassim, Birbal Bhaskar, Jing Yi, Karen Wamstad, Virginia Paton	2012	57
10	Results of a Multicenter Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant Clinical Cancer Research ·A. Keith Stewart, Christine I. Chen, Kang Howson‐Jan, Darrell White, Jean Roy, Michael J. Kovacs, Chaim Shustik, Anna Sadura, Lois E. Shepherd, Keyue Ding, Ralph M. Meyer, Andrew R. Belch	2004	51
11	Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse Leukemia ·Meletios Α. Dimopoulos, Katja Weisel, Philippe Moreau, Larry D. Anderson, Darrell White, Jesús F. San Miguel, Pieter Sonneveld, Monika Engelhardt, Matthew Jenner, Alessandro Corso, Jan Dürig, Michel Pavic, Morten Salomo, Eva Casal, Shankar Srinivasan, Xin Yu, Tuong Vi Nguyen, Tsvetan Biyukov, Teresa Peluso, Paul G. Richardson	2020	41
12	A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial Blood ·A. Keith Stewart, Suzanne Trudel, Nizar J. Bahlis, Darrell White, Waleed Sabry, Andrew R. Belch, Tony Reiman, Jean Roy, Chaim Shustik, Michael J. Kovacs, Jonathan Sussman, Ralph M. Meyer, Erica Harnett, Oana Dănilă, Judy Anne Chapman, Lois E. Shepherd	2010	36
13	Outcome of Hematopoietic Stem Cell Transplant Recipients Admitted to the Intensive Care Unit Biology of Blood and Marrow Transplantation ·Andrea Kew, Stephen Couban, Ward Patrick, Kara Thompson, Darrell White	2006	35
14	Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR Blood ·Meletios Α. Dimopoulos, David S. Siegel, Darrell White, Ralph V. Boccia, Karim Iskander, Zhao Yang, Amy Kimball, Khalid Mezzi, Heinz Ludwig, Rubén Niesvizky	2018	29
15	A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results Blood ·Paul G. Richardson, Sundar Jagannath, Philippe Moreau, Andrzej Jakubowiak, Marc S. Raab, Thierry Façon, Ravi Vij, Darrell White, Donna Reece, Lotfi Benboubker, Jeffrey A. Zonder, Wei Deng, Glenn S. Kroog, Anil Singhal, Sagar Lonial	2012	29
16	Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM) Blood ·Jonathan L. Kaufman, Saad Z. Usmani, Jesús F. San Miguel, Nizar J. Bahlis, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, P. Joy Ho, Kihyun Kım, Naoki Takezako, Philippe Moreau, Maria Krevvata, Huiling Pei, Jon Ukropec, Thomas Renaud, Sonali Trivedi, Rachel Kobos, Meletios Α. Dimopoulos	2019	28
17	Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux Blood ·Meletios Α. Dimopoulos, Darrell White, Lofti Benboubker, Gordon Cook, Merav Leiba, James Morton, P. Joy Ho, Kihyun Kım, Naoki Takezako, Sonali Trivedi, Kaida Wu, Tineke Casneuf, Christopher Chiu, Jordan M. Schecter, Philippe Moreau	2017	28
18	Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Blood ·Paul G. Richardson, Sundar Jagannath, Philippe Moreau, Andrzej Jakubowiak, Marc S. Raab, Thierry Façon, Ravi Vij, Darrell White, Donna Reece, Lotfi Benboubker, Jeffrey A. Zonder, L. Claire Tsao, Kenneth C. Anderson, Eric Bleickardt, Anil Singhal, Sagar Lonial	2014	27
19	Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma Journal of Medical Economics ·Saad Z. Usmani, Jamie Cavenagh, Andrew R. Belch, Cyrille Hulin, Supratik Basu, Darrell White, Ajay K. Nooka, Annette Ervin‐Haynes, Wai Yiu, Yasir M. Nagarwala, Anne Berger, C. Pelligra, Songtao Guo, G. Binder, C.J. Gibson, Thierry Façon	2015	25
20	Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort Blood ·Sebastian Grosicki, Ulf‐Henrik Mellqvist, Łukasz Pruchniewski, Jacob Crafoord, Suzanne Trudel, Chang‐Ki Min, Darrell White, Adrían Alegre, Markus Hansson, Takashi Ikeda, Kazutaka Sunami, Eric Leip, Arthur J. Kudla, Gregory Finn, Youngil Koh	2022	24

About Darrell White

Darrell White is a scholar working on Hematology, Oncology, Genetics, Molecular Biology and Pathology and Forensic Medicine, having authored 134 papers that have together received 1.9k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (116 papers), Protein Degradation and Inhibitors (53 papers), Cancer Treatment and Pharmacology (34 papers), Peptidase Inhibition and Analysis (23 papers), Chronic Lymphocytic Leukemia Research (17 papers), Cancer therapeutics and mechanisms (13 papers), Lymphoma Diagnosis and Treatment (12 papers) and HIV/AIDS drug development and treatment (11 papers). The work is most often cited by research in Hematology (1.3k citations), Oncology (1.0k citations), Genetics (311 citations), Pathology and Forensic Medicine (456 citations) and Molecular Biology (998 citations). Darrell White has collaborated with scholars based in Canada, United States and Spain. Frequent co-authors include Donna Reece, Andrew R. Belch, Philippe Moreau, Nizar J. Bahlis, Tony Reiman, Lotfi Benboubker, Meletios Α. Dimopoulos, A. Keith Stewart, Paul G. Richardson and Christine I. Chen. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer, Frontiers in Oncology and European Journal Of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact